

Amendments to the Specification:

Please amend the specification as follows:

Please replace the paragraph starting at page 5, line 17, with the following rewritten paragraph:

Fig. 8 is a reverse phase HPLC chromatogram of a pyridylaminated sugar chain prepared from a CHO-derived antibody (a) and a YB2/0-derived antibody (b). It indicates that sugar chain patterns ~~patterns~~ vary with different antibody-producing cells, and, specifically with the YB2/0-derived antibody, the peak group (A-D) estimated to be devoid of fucose is increased.

Please replace the paragraph starting at page 7, line 8, with the following rewritten paragraph:

The present inventors have demonstrated for the first time that HM1.24 antigen is expressed in solid tumors other than hematopoietic tumors and that anti-HM1.24 antibody exhibits ~~exhibits~~ a cytotoxic activity via ADCC etc. As used herein, cells to which anti-HM1.24 antibody exhibits a anti-tumor effect are HM1.24 antigen-expressing solid tumors other than hematopoietic tumors, and specifically there can be mentioned head and neck cancer, small cell lung cancer, non-small cell lung cancer (including squamous-cell carcinoma, adenocarcinoma, large cell carcinoma, adenosquamous carcinoma, and polymorphic sarcomatoid cancer, or cancer containing sarcoma components etc.), esophageal cancer, breast cancer, gastric cancer, colon cancer, rectal cancer, hepatic cancer, biliary tract cancer, pancreatic cancer, ovarian cancer, cervical cancer, endometrial cancer, prostate cancer, kidney cancer, bladder cancer, skin cancer, brain tumor, pediatric solid tumor, malignant bone tumor and the like. There can also be mentioned metastasis and metastatic lesions of these solid tumors, and carcinomatous pleuritis, cancerous peritonitis and cancerous meningitis etc. associated with solid tumors.